We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Read MoreHide Full Article
Viking Therapeutics, Inc. (VKTX - Free Report) closed at $32.17 in the latest trading session, marking a -1.17% move from the prior day. This change lagged the S&P 500's daily loss of 0.37%. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq decreased by 0.84%.
Shares of the company have depreciated by 5.54% over the course of the past month, outperforming the Medical sector's loss of 8.47%, and lagging the S&P 500's loss of 3.7%.
The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. On that day, Viking Therapeutics, Inc. is projected to report earnings of -$1.01 per share, which would represent a year-over-year decline of 146.34%.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.15 per share and a revenue of $0 million, indicating changes of -30.09% and 0%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Viking Therapeutics, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.53% lower. Viking Therapeutics, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 146, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today
Viking Therapeutics, Inc. (VKTX - Free Report) closed at $32.17 in the latest trading session, marking a -1.17% move from the prior day. This change lagged the S&P 500's daily loss of 0.37%. On the other hand, the Dow registered a loss of 0.18%, and the technology-centric Nasdaq decreased by 0.84%.
Shares of the company have depreciated by 5.54% over the course of the past month, outperforming the Medical sector's loss of 8.47%, and lagging the S&P 500's loss of 3.7%.
The investment community will be closely monitoring the performance of Viking Therapeutics, Inc. in its forthcoming earnings report. On that day, Viking Therapeutics, Inc. is projected to report earnings of -$1.01 per share, which would represent a year-over-year decline of 146.34%.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$4.15 per share and a revenue of $0 million, indicating changes of -30.09% and 0%, respectively, from the former year.
Investors might also notice recent changes to analyst estimates for Viking Therapeutics, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.53% lower. Viking Therapeutics, Inc. is currently sporting a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 146, which puts it in the bottom 41% of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.